O Amengual1, D Fujita2, E Ota3, L Carmona4, K Oku5, M Sugiura-Ogasawara6, A Murashima7, T Atsumi5. 1. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan olgaam@med.hokudai.ac.jp. 2. Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki City, Osaka, Japan. 3. Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan. 4. Institute for Musculoskeletal Health, Madrid, Spain. 5. Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 6. Department of Gynaecology, Nagoya City University Hospital, Nagoya, Japan. 7. Department of Rheumatology, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan.
Abstract
OBJECTIVE: Obstetric complications are common in patients with antiphospholipid syndrome. However, the impact of antiphosholipid antibodies (aPL) in the pregnancy outcomes of asymptomatic aPL carriers is uncertain. The aim of this systematic review is to assess whether primary prophylaxis is beneficial to prevent obstetric complications during pregnancy in asymptomatic women positive for aPL who have no history of recurrent pregnancy loss or intrauterine fetal death. METHODS: Studies evaluating the effect of prophylactic treatment versus no treatment in asymptomatic pregnant aPL carriers were identified in an electronic database search. Design, population and outcome homogeneity of studies was assessed and meta-analysis was performed. The pooled Mantel-Haenszel relative risk of specific pregnancy outcomes was obtained using random effects models. Heterogeneity was measured with the I(2) statistic. All analyses were conducted using Review Manager 5.3. RESULTS: Data from five studies involving 154 pregnancies were included and three studies were meta-analysed. The risk ratio and 95% confidence interval (CI) of live birth rates, preterm birth, low birth weight and overall pregnancy complications in treated and untreated pregnancies were 1.14 (0.18-7.31); 1.71 (0.32-8.98); 0.98 (0.07-13.54) and 2.15 (0.63-7.33),respectively. Results from the meta-analysis revealed that prophylactic treatment with aspirin is not superior to placebo to prevent pregnancy complications in asymptomatic aPL carriers. CONCLUSION: This systematic review did not find evidence of the superiority of prophylactic treatment with aspirin compared to placebo or usual care to prevent unfavourable obstetric outcomes in otherwise healthy women with aPL during the first pregnancy.
OBJECTIVE: Obstetric complications are common in patients with antiphospholipid syndrome. However, the impact of antiphosholipid antibodies (aPL) in the pregnancy outcomes of asymptomatic aPL carriers is uncertain. The aim of this systematic review is to assess whether primary prophylaxis is beneficial to prevent obstetric complications during pregnancy in asymptomatic women positive for aPL who have no history of recurrent pregnancy loss or intrauterine fetal death. METHODS: Studies evaluating the effect of prophylactic treatment versus no treatment in asymptomatic pregnant aPL carriers were identified in an electronic database search. Design, population and outcome homogeneity of studies was assessed and meta-analysis was performed. The pooled Mantel-Haenszel relative risk of specific pregnancy outcomes was obtained using random effects models. Heterogeneity was measured with the I(2) statistic. All analyses were conducted using Review Manager 5.3. RESULTS: Data from five studies involving 154 pregnancies were included and three studies were meta-analysed. The risk ratio and 95% confidence interval (CI) of live birth rates, preterm birth, low birth weight and overall pregnancy complications in treated and untreated pregnancies were 1.14 (0.18-7.31); 1.71 (0.32-8.98); 0.98 (0.07-13.54) and 2.15 (0.63-7.33),respectively. Results from the meta-analysis revealed that prophylactic treatment with aspirin is not superior to placebo to prevent pregnancy complications in asymptomatic aPL carriers. CONCLUSION: This systematic review did not find evidence of the superiority of prophylactic treatment with aspirin compared to placebo or usual care to prevent unfavourable obstetric outcomes in otherwise healthy women with aPL during the first pregnancy.
Authors: Mancy Tong; Teimur Kayani; Deidre M Jones; Jane E Salmon; Shannon Whirledge; Lawrence W Chamley; Vikki M Abrahams Journal: Arthritis Rheumatol Date: 2022-04-27 Impact factor: 15.483
Authors: Cecile M Yelnik; Carl A Laskin; T Flint Porter; D Ware Branch; Jill P Buyon; Marta M Guerra; Michael D Lockshin; Michelle Petri; Joan T Merrill; Lisa R Sammaritano; Mimi Y Kim; Jane E Salmon Journal: Lupus Sci Med Date: 2016-01-12
Authors: Carlos Tortosa; Oscar Cabrera-Marante; Manuel Serrano; José A Martínez-Flores; Dolores Pérez; David Lora; Luis Morillas; Estela Paz-Artal; José M Morales; Daniel Pleguezuelo; Antonio Serrano Journal: PLoS One Date: 2017-07-20 Impact factor: 3.240
Authors: Micaela Fredi; Laura Andreoli; Elena Aggogeri; Elisa Bettiga; Maria Grazia Lazzaroni; Véronique Le Guern; Andrea Lojacono; Nathalie Morel; Jean Charles Piette; Sonia Zatti; Nathalie Costedoat-Chalumeau; Angela Tincani Journal: Front Immunol Date: 2018-05-07 Impact factor: 7.561